HumoralImmunity

Humoral immunity is initiated when naïve B cells recognize antigen via their B-cell receptor (surface IgM/IgD). For T-dependent antigens (typically proteins), B cells internalize and present antigen on MHC class II to helper T cells (Th2 predominantly), receiving CD40L-CD40 and cytokine signals (IL-4, IL-5, IL-6, IL-21) that drive proliferation, germinal center formation, somatic hypermutation, affinity maturation, and class switch recombination. This produces high-affinity IgG, IgA, or IgE and generates long-lived plasma cells and memory B cells. T-independent antigens (e.g., polysaccharide capsules) can directly cross-link BCRs, producing a weaker, mainly IgM response without memory—explaining poor immunogenicity of polysaccharide antigens in infants and the rationale for conjugate vaccines (e.g., Hib, pneumococcal conjugate) that link polysaccharide to protein carriers to recruit T-cell help.

Antibodies function via several mechanisms: neutralization (blocking viral entry or toxin binding), opsonization (enhancing phagocytosis via Fc receptors), and complement activation (classical pathway, leading to membrane attack complex formation and further opsonization via C3b). IgG is the major antibody in secondary responses and crosses the placenta; IgA mediates mucosal immunity; IgM is the first antibody produced (pentamer, potent complement activator); IgE is involved in defense against helminths and allergic responses.

Clinical relevance: Humoral immunodeficiencies (e.g., X-linked agammaglobulinemia, Common Variable Immunodeficiency, IgA deficiency, Hyper-IgM syndrome) predispose to recurrent infections with encapsulated bacteria (Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis) due to impaired opsonization and antibody-mediated clearance. Understanding humoral immunity underlies vaccine design, autoimmune disease mechanisms (autoantibody production), and monoclonal antibody therapeutics.